Effects of Mifepristone on Rabbit Intraocular Pressure in the Presence and Absence of Dexamethasone

Green, Keith; Cheeks, Lisa; Slagle, Tracey; Phillips, C I

doi:10.1159/000267030

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More studies are required to determine the effects. Topical mifepristone preparation is being evaluated for the treatment of corticosteroid-induced intraocular pressure [85][86][87].…”

Section: Meningiomamentioning

confidence: 99%

Clinical Utility of Mifepristone: Apprising the Expanding Horizons

Karena¹,

Shah²,

Vaghela³

et al. 2022

Cureus

View full text Add to dashboard Cite

Mifepristone is a progesterone and glucocorticoid receptor antagonist. Medical abortion with mifepristone and prostaglandin has revolutionized the abortion process extending abortion care to the doors of females. From as low as 2 mg/day to doses extending to 600 mg, from daily dosing to single dosage treatment, mifepristone has a wide perspective in the treatment of various pathologies. Cervical dilatation and myometrial contractility have made the utility of mifepristone feasible for second-trimester termination of pregnancy and induction of labor awaiting Food and Drug Administration approvals. Its anti-progesterone action on the menstrual cycle has a new dimension of use as a contraceptive, as well as use as a menstruation inductive agent. Its role in endometriosis, ectopic pregnancy, and adenomyosis requires more intensive research. Apoptotic action of mifepristone, interference of heterotypic cell adhesion to the basement membrane, cell migration, growth inhibition of various cancer cell lines, decreased epidermal growth factor expression, suppression of invasive and metastatic cancer potential, increase in tumor necrosis factor, downregulation of cyclin-dependent kinase 2, B-cell lymphoma 2, and Nuclear factor kappa B have opened its potential to be explored as anti-cancer treatment and its effects on leiomyoma. The drug needs to be studied more for the prospectus of its anti-glucocorticoid actions in a wider dimension beyond its acquiescence for the treatment of Cushing syndrome.

show abstract

“…More studies are required to determine the effects. Topical mifepristone preparation is being evaluated for the treatment of corticosteroid-induced intraocular pressure [85][86][87].…”

Section: Meningiomamentioning

confidence: 99%

Clinical Utility of Mifepristone: Apprising the Expanding Horizons

Karena¹,

Shah²,

Vaghela³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…En estudios experimentales se observó que animales tratados con mifepristona y a continuación con dexametasona no mostraron un incremento de la PIO (48).…”

Section: Antagonistas De Los Receptores De Esteroidesunclassified

Nuevos desarrollos en el tratamiento médico del glaucoma

Muñoz‐Negrete

Pérez-López

Kim

et al. 2009

Arch Soc Esp Oftalmol

View full text Add to dashboard Cite

The medical treatment of glaucoma has undergone significant development in recent years. Research in this field is focused on improving pre-existing drugs and on the development of new molecules. In relation to commercial drugs, there is a trend to improve local tolerance, using less toxic preservatives as in the case of sofZIA in travoprost, and eliminating the preservatives as in tafluprost. The development of new, fixed combinations of commercial drugs could also enhance their administration and therapeutic compliance. There is also intense research activity in the search for new therapeutic groups for glaucoma treatment. Calcium channel-blockers such as lomerizine do not seem to affect systemic hypotension, while topical calcium-blockers like flunarizine and iganidipine are also under research. Endothelin 1 antagonists such as sulfisoxazole and bunazosine could be also useful in the treatment of glaucoma. In the renin angiotensin system, angiotensin (1-7) and olmesartan are under investigation for use in glaucoma patients. Trabecular drugs such as Rho-kinase inhibitors could be effective on the pathogenic mechanism of primary open angle glaucoma. Finally, topical mifepristone, an antagonist of glucocorticoid receptors, is under evaluation for corticosteroid-induced elevated intraocular pressure (Arch Soc Esp Oftalmol 2009; 84: 491-500).

show abstract